← 返回新闻首页

New cervical cancer vaccine to be added to national immunisation schedules from Jan 1, 2027

Singaporean and permanent resident females aged 9 to 26 will have access to broader protection against cervical cancer from Jan 1, 2027, when a new vaccine is added to the national immunisation schedules.In a joint statement on Friday (Oct 2), the Ministry of Health (MOH), Communicable Diseases Agency and Health Promotion Board said the HPV9 vaccine, also known as Gardasil...

AsiaOne Singapore2026-10-02 18:08查看原文 ↗

New cervical cancer vaccine to be added to national immunisation schedules from Jan 1, 2027

In a joint statement on Friday (Oct 2), the Ministry of Health (MOH), Communicable Diseases Agency and Health Promotion Board said the HPV9 vaccine, also known as Gardasil 9, will be included in the National Childhood Immunisation Schedule (NCIS) and National Adult Immunisation Schedule (NAIS).

Currently, the HPV2 vaccine, also known as Cervarix, is included in both schedules and will remain available as an alternative option when HPV9 is added.

Both vaccines protect against HPV strains that cause about 70 per cent of cervical cancers.

However, the agencies noted that the HPV9 vaccine provides broader protection by also covering additional HPV types that account for a further 20 per cent of cervical cancers, bringing its total coverage to about 90 per cent.

Updated vaccination recommendations

Under updated recommendations by the Expert Committee on Immunisation, unvaccinated females can start or complete their vaccination series with either HPV2 or HPV9.

Those receiving their first dose between the ages of 9 and 14 will require two doses, while those starting vaccination between the ages of 15 and 26 will require three doses.

If vaccination has been started but not completed by age 26, the remaining doses can be taken after age 26, as early as possible and up to age 45.

Females who have started but not completed their vaccination series with previous vaccines may complete it with HPV9, while those who have already completed their recommended schedule are not advised to receive additional HPV9 doses.

HPV9 will also replace HPV2 for female students who have yet to start or complete their vaccination series from Jan 1 next year.

Female students who received HPV2 as their first dose in 2026, including those from the 2026 Secondary 1 cohort, will complete their series in schools in 2027 with HPV9 as their second dose.

HPV vaccinations are currently provided at no charge to Secondary 1 and 2 female students.

Those who have already completed their recommended vaccination series will not be eligible for additional HPV9 doses.

From Jan 1, 2027, eligible Singaporean children will receive full subsidies for the HPV9 vaccine at CHAS GP clinics and polyclinics.

Eligible Singaporean adults will receive means-tested subsidies of up to 75 per cent, while eligible permanent residents will receive subsidies at polyclinics.

MediSave use for HPV9 vaccination will also be extended to those in the recommended groups under the NCIS and NAIS, subject to the MediSave Chronic and Preventive Care limits of $700 or $1,000.

Vaccination subsidies and MediSave use will not apply to additional HPV9 doses for individuals who have already completed their recommended vaccination schedule.

Eligible individuals can book HPV vaccination appointments at participating CHAS GP clinics through the national vaccination booking portal or make an appointment at a polyclinic.

xingying.koh@asiaone.com

从 2027 年 1 月 1 日起，9 至 26 岁的新加坡公民和永久居民女性将获得更广泛的宫颈癌保护，届时一种新的疫苗将被纳入国家免疫计划。

卫生部、传染病机构和健康促进局于周五（10 月 2 日）发表联合声明称，HPV9 疫苗（又称 Gardasil 9）将被纳入国家儿童免疫计划 (NCIS) 和国家成人免疫计划 (NAIS)。

目前，HPV2疫苗（也称为Cervarix）已包含在两个接种计划中，并且在HPV9疫苗加入后仍将作为一种替代选择。

这两种疫苗都能预防导致约 70% 宫颈癌的 HPV 病毒株。

然而，这些机构指出，HPV9 疫苗通过覆盖其他 HPV 类型（这些类型占宫颈癌病例的 20%）提供更广泛的保护，使其总覆盖率达到约 90%。

更新的疫苗接种建议

根据免疫专家委员会的最新建议，未接种疫苗的女性可以开始或完成 HPV2 或 HPV9 疫苗接种系列。

9至14岁首次接种疫苗者需要接种两剂，而15至26岁首次接种疫苗者需要接种三剂。

如果 26 岁之前已经开始接种疫苗但尚未完成，剩余的剂量可以在 26 岁之后尽早接种，最晚可至 45 岁。

已经开始接种但尚未完成先前疫苗接种程序的女性，可以接种 HPV9 疫苗来完成接种；而已经完成推荐接种程序的女性，不建议接种额外的 HPV9 疫苗。

从明年1月1日起，HPV9疫苗也将取代HPV2疫苗，用于尚未开始或完成疫苗接种程序的女学生。